F-096

Appl. No. 10/035,100 Amdt. dated September 29, 2004 Reply to Office Action of August 17, 2004

REMARKS

6

Claims 1, 3, 4, 7-9, 11-13, 15-16, and 18 remain in the application. New claims 23-25 are submitted herewith. Following entry of the present amendment, Claims 1, 9, 18, and 23-25 are in independent form.

New Claims 23-25 do not raise any issues of new matter.

Claims 1, 3, 4, 7-9, 11-13, 15-16, and 18 stand rejected under 35 U.S.C. § 103(a) as allegedly be unpatentable over Bymaster, et al., EP 0830864 (hereinafter referred to "Bymaster").

As stated in the Office Action, Bymaster teaches combination compositions comprising an atypical antipsychotic agent and a serotonin reuptake inhibitor and the therapy for treatment of schizophrenia. See, page 12, lines 50-51, as well as the various combinations at the bottom of page 3. The claims differ in that Bymaster does not recite the serotonin reuptake inhibitor reboxetine. Applicants respectfully submit that reboxetine is a well known norepinephrine reuptake inhibitor (as stated on page 1, lines 15-16) rather than a serotonin reuptake inhibitor as taught in "Bymaster". Since "Bymaster" only teaches the combination of atypical antipsychotic with a serotonin reuptake inhibitor, Applicants submit that "Bymaster" does not render obvious the presently claims invention. Accordingly, Applicants respectfully request reconsideration of the presently pending rejection.

In view of the present amendment and foregoing remarks, reconsideration of the rejection and advance of the case to issue are respectfully requested.

7

Appl. No. 10/035,100 Amdt, dated September 29, 2004 Reply to Office Action of August 17, 2004

The Commissioner is authorized to charge any fee or credit any overpayment in connection with the communication to our deposit account number 23-0455.

Respectfully submitted,

David R. Kurlandsky Registration No. 41,505

Warner-Lambert Company

2800 Plymouth Road Ann Arbor, MI 48105

Telephone: (734) 622-7304 Facsimile: (734) 622-1553